| Results Confirm High Response Rates and Low Incidence of Serious Side Effects BERKELEY HEIGHTS, N.J., Dec. 8, 2011 (GLOBE NEWSWIRE) -- Genta Incorporated (OTCBB:GNTA.OB) today announced presentation of results from the Company's Phase 2b clinical trial using tesetaxel as initial, single-agent chemotherapy in women with advanced breast cancer. The trial is lead by Memorial Sloan-Kettering Cancer Center, New York, NY, in collaboration with three other U.S. based cancer centers. The data are being pr...continued GNTA trials pharma paclitaxel |
Thursday, December 8, 2011
Genta Announces Results From Clinical Trial of Tesetaxel as Initial Chemotherapy for Women With Recurrent Breast Cancer
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment